LDLR and glioblastoma: This was determined through immunohistochemistry (IHC) using an LDL-receptor targeting antibody carried out on patient-derived tissue microarrays (TMA), which incorporated varying intra-tumour regions in the adult GBM cohort and single region samples for the paediatric HGGs.